Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» rheumatoid arthritis
rheumatoid arthritis
Oxford BioDynamics and Kings College London to advance rheumatoid arthritis treatment
Biopharma Reporter
Thu, 05/16/24 - 11:30 am
Oxford BioDynamics
King's College
EpiSwitch
rheumatoid arthritis
abatacept
Alfasigma to acquire Galapagos’ Jyseleca business
Pharmaceutical Business Review
Tue, 01/2/24 - 09:58 am
Galapagos
Alfasigma
Jyseleca
filgotinib
ulcerative colitis
rheumatoid arthritis
Aclaris shares plummet on terminating development of rheumatoid arthritis drug
Reuters
Mon, 11/13/23 - 10:00 am
Aclaris
Therapeutics
rheumatoid arthritis
clinical trials
zunsemetinib
Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis
Biopharma Reporter
Thu, 11/9/23 - 09:55 am
Janssen
JNJ
rheumatoid arthritis
nipocalimab
clinical trials
Here come the PD-1 agonists
EP Vantage
Tue, 05/23/23 - 09:49 am
PD-1 agonists
autoimmune disease
Eli Lilly
rheumatoid arthritis
peresolimab
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Drugs.com
Thu, 05/18/23 - 08:32 pm
Eli Lilly
peresolimab
rheumatoid arthritis
clinical trials
Gilead, EVOQ Unite on 'Potential Breakthrough' Treatment for RA, Lupus
BioSpace
Tue, 01/3/23 - 10:28 pm
Gilead Sciences
Evoq Therapeutics
lupus
rheumatoid arthritis
GSK dumps major pipeline prospect otilimab on lackluster phase 3 data in rheumatoid arthritis
Fierce Biotech
Thu, 10/27/22 - 10:48 am
GSK
otilimab
rheumatoid arthritis
Big pharma’s key third-quarter data
EP Vantage
Tue, 06/28/22 - 10:37 am
GSK
Roche
Pfizer
JNJ
AstraZeneca
Novo Nordisk vaccines
clinical trials
pneumococcal disease
crovalimab
rheumatoid arthritis
J&J, BMS arthritis drugs lowered death risk among COVID patients in federal study
Fierce Pharma
Thu, 06/2/22 - 07:29 pm
JNJ
Bristol Myers Squibb
COVID-19
rheumatoid arthritis
clinical trials
Orencia
Remicade
Biogen and Xbrane in deal on rheumatoid arthritis targeting biosimilar
Biopharma Reporter
Mon, 02/14/22 - 11:04 am
Biogen
Xbrane Biopharma
monoclonal antibodies
Xcimzane
Cimzia
rheumatoid arthritis
Galvani Bioelectronics implants first neurostimulator for splenic nerve stimulation in rheumatoid arthritis patient
MedCity News
Mon, 02/7/22 - 11:23 am
GSK
Verily
Galvani Bioelectronics
neurostimulation
rheumatoid arthritis
splenic nerve stimulation
Scipher Medicine’s blood test shows the benefits of precision medicine in rheumatoid arthritis
MedCity News
Tue, 02/1/22 - 10:21 am
Scipher Medicine
precision medicine
PrismRA
rheumatoid arthritis
Medtech
diagnostics
A three-decade monopoly: How Amgen built a patent thicket around its top-selling drug
BioPharma Dive
Mon, 11/1/21 - 11:56 am
Amgen
Enbrel
rheumatoid arthritis
patents
How Researchers Stumbled Upon an Arthritis Vaccine Just in Time for World Arthritis Day
Xtalks
Tue, 10/12/21 - 11:37 pm
vaccines
rheumatoid arthritis
Galapagos avoids 'complete whiff' as key anti-inflammatory drug fails to beat placebo in midphase trials
Fierce Biotech
Thu, 07/15/21 - 12:25 pm
Galapagos
clinical trials
rheumatoid arthritis
ulcerative colitis
psoriasis
filgotinib
Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial
Yahoo/Benzinga
Thu, 06/3/21 - 11:03 am
Eli Lilly
clinical trials
rheumatoid arthritis
olumiant
AbbVie's Rinvoq rollout on track despite JAK safety concerns, but uncertainty remains: analyst
Fierce Pharma
Thu, 04/22/21 - 11:42 pm
AbbVie
Rinvoq
Xeljanz
FDA
rheumatoid arthritis
AbbVie's approval delay raises further concerns about JAK drugs
BioPharma Dive
Thu, 03/18/21 - 08:26 pm
AbbVie
FDA
Rinvoq
rheumatoid arthritis
FDA holds back from action over Xeljanz safety study FDA holds back from action over Xeljanz safety study
Pharmaforum
Fri, 02/5/21 - 10:40 am
Pfizer
FDA
Xeljanz
rheumatoid arthritis
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »